[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351586-105":59,"doc-detail-351586-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","atorvastatin-promotes-lipid-catabolism-in-colorectal-cancer-via-fdft1-mediated-inhibition-of-the-pi3kakt-pathway","Atorvastatin promotes lipid catabolism in colorectal cancer via FDFT1-mediated inhibition of the PI3K/AKT pathway","","Atorvastatin (ATST), an HMGCR inhibitor, is widely studied for antitumor activity, yet its precise mechanism remains incompletely defined. In mice, ATST suppresses AOM/DSS-induced colorectal cancer (CRC) progression. Mechanistically, ATST inhibits HMGCR and depletes cellular cholesterol, triggering the SREBP2–FDFT1 axis. This axis blocks the PI3K/AKT pathway, provoking endoplasmic reticulum (ER) stress and autophagy while promoting lipid catabolism to drive ferroptosis. The findings clarify how ATST controls lipid catabolism to modulate CRC progression and suggest a new therapeutic direction.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/atorvastatin-promotes-lipid-catabolism-in-colorectal-cancer-via-fdft1-mediated-inhibition-of-the-pi3kakt-pathway/351586/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/atorvastatin-promotes-lipid-catabolism-in-colorectal-cancer-via-fdft1-mediated-inhibition-of-the-pi3kakt-pathway/351586.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main finding about atorvastatin in colorectal cancer?","Question",{"text":112,"@type":113},"Atorvastatin inhibits AOM/DSS-induced colorectal cancer progression in mice. It links this effect to lipid catabolism controlled through specific signaling events.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does atorvastatin mechanistically influence the proposed pathway?",{"text":117,"@type":113},"Atorvastatin inhibits HMGCR, depletes cellular cholesterol, and activates the SREBP2–FDFT1 axis. This in turn inhibits the PI3K/AKT pathway and promotes ferroptosis-associated processes.",{"name":119,"@type":110,"acceptedAnswer":120},"What cellular outcomes are reported downstream of PI3K/AKT inhibition?",{"text":121,"@type":113},"The study reports induction of endoplasmic reticulum (ER) stress and autophagy, alongside promotion of lipid catabolism that drives ferroptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351586,1790156168,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Xu etal. Cell Communication and Signaling (2026) 24:259  \n[https://doi.org/10.1186/s12964-026-02802-6](https://doi.org/10.1186/s12964-026-02802-6)  \nCell Communication and Signaling  \nRESEARCH Open Access  \nAtorvastatin promotes lipid catabolism in colorectal cancer via FDFT1‒mediated inhibition of the PI3K/AKT pathway  \nJiale Xu1, Xiaoyu Qin1, Longying Xiong2, Cheng Zhao2, Dan Ge2, Yanping Wu2, Yixuan Shen2, Mengli Yang2, Bihan Shen2, Min Chen1 and Chen Min1*  \nAbstract  \nAs a hydroxymethylglutaryl‒coenzyme A reductase (HMGCR) inhibitors, atorvastatin (ATST) has garnered widespread attention because of its antitumor effects. However, its specific mechanism of action remains incompletely understood. In our study, ATST was found to inhibit AOM/DSS‒induced colorectal cancer (CRC) progression in mice. Mechanistically, by inhibiting HMGCR and depleting cellular cholesterol, ATST activates the SREBP2‒FDFT1 axis. This in turn inhibits the PI3K/AKT pathway, inducing endoplasmic reticulum (ER) stress and autophagy while concurrently promoting lipid catabolism to drive ferroptosis. This study elucidates the mechanism through which ATST regulates lipid catabolism to influence CRC progression, providing a new direction for CRC therapy.  \nKeywords Atorvastatin, Colorectal cancer, PI3K/AKT pathway, FDFT1, ER stress, Lipid catabolism  \nIntroduction  \nIn recent years, cancer has become one of the leading causes of death worldwide. Among the various types of cancer, colorectal cancer (CRC) ranks as the third most commonly diagnosed cancer and the second leading cause of cancer‒related deaths globally [1]. In China, both the incidence and mortality rates of CRC continue to increase gradually [2]. Although progress has been made in the treatment of CRC, drug resistance remains a major obstacle that severely limits therapeutic efficacy.  \n*Correspondence:  \nChen Min  \n[croweminchan@nju.edu.cn](croweminchan@nju.edu.cn)  \n1Department of Gastroenterology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing City 210008, Jiangsu Province, P. R. China  \n2Department of Gastroenterology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing City 210008, Jiangsu Province, P. R. China  \nThe development of new drugs still falls short of meeting the current clinical demands for CRC therapy. Therefore, the new and more cost‒effective strategies for drug development are urgently needed.  \nTo address the high costs and risks associated with traditional drug development, drug repurposing has become a prominent innovative therapeutic strategy. The review by Kirtonia et al. provides strong evidence for the feasibility of this strategy and its multiple advantages, including shortened development timelines, reduced costs, and improved safety profiles [3] . Hydroxy methyl glutaryl‒CoA (HMG‒CoA) reductase inhibitors, commonly known as atorvastatin (ATST), act as the rate‒limiting enzymes in the mevalonate pathway and are potent cholesterol‒lowering agents [4] . Studies have revealed that in addition to inhibiting de novo cholesterol synthesis and modulating low‒density lipoprotein receptor expression to reduce plasma cholesterol levels [5], ATST also have  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the materia","cbCaid0uI5lCUFdF","https://ap.wps.com/l/cbCaid0uI5lCUFdF","pdf",6200070,"English","# Abstract\n# Introduction\n## Background and clinical need\n## Drug repurposing and statins\n## Links to metabolism, ER stress, and cancer progression","[{\"question\":\"What is the main finding about atorvastatin in colorectal cancer?\",\"answer\":\"Atorvastatin inhibits AOM/DSS-induced colorectal cancer progression in mice. It links this effect to lipid catabolism controlled through specific signaling events.\"},{\"question\":\"How does atorvastatin mechanistically influence the proposed pathway?\",\"answer\":\"Atorvastatin inhibits HMGCR, depletes cellular cholesterol, and activates the SREBP2–FDFT1 axis. This in turn inhibits the PI3K/AKT pathway and promotes ferroptosis-associated processes.\"},{\"question\":\"What cellular outcomes are reported downstream of PI3K/AKT inhibition?\",\"answer\":\"The study reports induction of endoplasmic reticulum (ER) stress and autophagy, alongside promotion of lipid catabolism that drives ferroptosis.\"}]","Atorvastatin promotes lipid catabolism in colorectal cancer via FDFT1-mediated inhibition of the PI3K/AKT pathway | PDF",1790094840,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1848539498df735ef3243736d3e52930.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a0973237ae4fbf03a10df9c3a21489c.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c5d5a7322033368ce9ced52163b5bca.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4efa818bf0ff4b9a39ca2b73114548cb.webp",980,1306]